Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
Total Valuation
Aldeyra Therapeutics has a market cap or net worth of $301.52M. The enterprise value is -$54.51T.
Market Cap$301.52M
Enterprise Value-$54.51T
Share Statistics
Aldeyra Therapeutics has 60,182,780 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,182,780
Owned by Insiders12.93%
Owned by Institutions1.29%
Financial Efficiency
Aldeyra Therapeutics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is >-0.01%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)>-0.01%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee0.00
Profits Per Employee-3.76T
Employee Count9
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aldeyra Therapeutics is ―. Aldeyra Therapeutics’s PEG ratio is 0.23.
PE Ratio―
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow<0.01
PEG Ratio0.23
Income Statement
In the last 12 months, Aldeyra Therapeutics had revenue of 0.00 and earned -33.85M in profits. Earnings per share was -0.56.
Revenue0.00
Gross Profit-251.99K
Operating Income-35.27M
Pretax Income-33.85M
Net Income-33.85M
EBITDA-31.69M
Earnings Per Share (EPS)-0.56
Cash Flow
In the last 12 months, operating cash flow was 28.20T and capital expenditures -4.00, giving a free cash flow of 28.20T billion.
Operating Cash Flow28.20T
Free Cash Flow28.20T
Free Cash Flow per Share468.49K
Dividends & Yields
Aldeyra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.33
52-Week Price Change-28.22%
50-Day Moving Average5.02
200-Day Moving Average4.81
Relative Strength Index (RSI)52.03
Average Volume (3m)802.07K
Important Dates
Aldeyra Therapeutics upcoming earnings date is Apr 30, 2026, Before Open (Confirmed).
Last Earnings DateMay 6, 2025
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Aldeyra Therapeutics as a current ratio of 2.58, with Debt / Equity ratio of 35.10%
Current Ratio2.58
Quick Ratio2.58
Debt to Market Cap49.92K
Net Debt to EBITDA1.72M
Interest Coverage Ratio-18.51
Taxes
In the past 12 months, Aldeyra Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aldeyra Therapeutics EV to EBITDA ratio is 1.72M, with an EV/FCF ratio of 1.63.
EV to Sales0.00
EV to EBITDA1.72M
EV to Free Cash Flow1.63
EV to Operating Cash Flow1.63
Balance Sheet
Aldeyra Therapeutics has $70.04T in cash and marketable securities with $15.53T in debt, giving a net cash position of $54.51T billion.
Cash & Marketable Securities$70.04T
Total Debt$15.53T
Net Cash$54.51T
Net Cash Per Share$905.76K
Tangible Book Value Per Share$736.81K
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aldeyra Therapeutics is $9.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$9.50
Price Target Upside80.61% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast4.23%